Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05009732 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
A Phase 3 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Terminated
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
NCT05009732 is a Phase 3 study that was terminated before completion, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 139 participants.
The verdict
NCT05009732, a Phase 3 study, was terminated before completion, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
Study Summary
This study is an adaptive Phase III randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted globally. The study will compare GT0918 plus standard of care (SOC) with the placebo plus SOC. Approximately 762 subjects will be randomized in a 1:1 ratio to either GT0918 plus SOC or placebo plus SOC group.
Interventions
- DRUG Matching placebo
- DRUG Standard of care
- DRUG GT0918
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05009732
The ClinicalTrials.gov registry entry for NCT05009732 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Kintor Pharmaceutical Inc,, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching placebo is the first listed.
NCT05009732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05009732 about?
NCT05009732 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects". This study is an adaptive Phase III randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted globally. The study will compare GT0918 plus stan...
What is the current status of trial NCT05009732?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2021-09-30. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05009732?
The interventions under investigation include: Matching placebo (DRUG), Standard of care (DRUG), GT0918 (DRUG).
Who is sponsoring clinical trial NCT05009732?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.